Lundbeck has not had much news to report recently, and several analysts are struggling to pinpoint what is needed in the short term to give the Danish pharmaceutical company wind in its sails on the stock exchange.
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN
You might need a flashlight to make out what is keeping Lundbeck afloat at the moment.
The pharmaceutical company's pipeline of future drug candidates remains all but empty, and potential acquisitions have, by the looks of things, been paused.
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.